ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $40.00

ArriVent BioPharma (NASDAQ:AVBP) had its price target increased by HC Wainwright from $39.00 to $40.00 in a report released on Wednesday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for ArriVent BioPharma’s Q2 2025 earnings at ($0.78) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.78) EPS, FY2025 earnings at ($4.26) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.73) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.80) EPS and FY2026 earnings at ($2.99) EPS.

Other equities research analysts have also issued research reports about the stock. B. Riley started coverage on shares of ArriVent BioPharma in a report on Thursday, March 20th. They issued a “buy” rating and a $37.00 target price for the company. Guggenheim assumed coverage on shares of ArriVent BioPharma in a research note on Monday, March 10th. They issued a “buy” rating and a $45.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $39.17.

ArriVent BioPharma Price Performance

NASDAQ:AVBP opened at $19.36 on Wednesday. The firm has a market capitalization of $662.36 million, a price-to-earnings ratio of -5.14 and a beta of 1.47. The business has a 50 day simple moving average of $19.25 and a 200-day simple moving average of $24.50. ArriVent BioPharma has a 1 year low of $15.47 and a 1 year high of $36.37.

ArriVent BioPharma (NASDAQ:AVBP) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($1.24). As a group, analysts expect that ArriVent BioPharma will post -2.74 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its holdings in ArriVent BioPharma by 1,124.8% during the 3rd quarter. Barclays PLC now owns 41,522 shares of the company’s stock valued at $976,000 after buying an additional 38,132 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of ArriVent BioPharma by 183.2% during the third quarter. JPMorgan Chase & Co. now owns 12,445 shares of the company’s stock worth $292,000 after acquiring an additional 8,050 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in shares of ArriVent BioPharma during the fourth quarter valued at approximately $190,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of ArriVent BioPharma during the fourth quarter valued at approximately $31,000. Finally, Rhumbline Advisers boosted its holdings in shares of ArriVent BioPharma by 9.1% in the fourth quarter. Rhumbline Advisers now owns 36,690 shares of the company’s stock valued at $977,000 after purchasing an additional 3,069 shares during the period. 9.48% of the stock is currently owned by institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.